Rizatriptan
As of the edition of 20 October 2026, Rizatriptan is a small molecule: marketed, first approved in 1998 (US); acts on HTR1B and HTR1D; no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Small molecule
- Brand name
- Maxalt
- First approved
- 29 June 1998 (US)
- Approvals on record
- 11 in 4 regions
- Holder of the most recent approval
- Gensco Pharma; 6 holders in all
- Registered trials
- 19, 0 stopped early
- Disease areas
- Nervous system
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Gensco Pharma holds a later exclusivity on its own new formulation or combination product, ending 2034; it does not protect the original drug.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Rizatriptan.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 3 | 15 | 15 | 0 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 19 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Organon | Acquired holder and Lead sponsor of trials | 1995 to now |
| IntelGenx | Later holder | 2023 to now |
| Gensco Pharma | Acquired holder | 2023 to now |
| Merck & Co. | Originator | 1998 to 2022 |